DS
AUTL

David Shaw’s Autolus Therapeutics AUTL Stock Holding History

David Shaw’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-91,687
Closed -$333K – 4404
2024
Q3 		$333K Sell
91,687
-491,178
-84% -$1.96M ﹤0.01% 3927
2024
Q2 		$2.03M Sell
582,865
-64,094
-10% -$277K ﹤0.01% 2647
2024
Q1 		$4.13M Buy
646,959
+425,470
+192% +$2.65M ﹤0.01% 2031
2023
Q4 		$1.43M Buy
+221,489
New +$845K ﹤0.01% 2900
2021
Q3 		– Sell
-32,500
Closed -$216K – 4952
2021
Q2 		$216K Buy
+32,500
New +$202K ﹤0.01% 4419

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

David Shaw's AUTL Position: Q4 2024 in Review

David Shaw sold out of Autolus Therapeutics (AUTL) in Q4 2024, closing a stake of 91,687 shares — an estimated $333K sold.

David Shaw first reported a position in AUTL in Q2 2021 and held it in 5 quarters. The position peaked at $4.13M in Q1 2024. 110 funds tracked by Wall St. Rank hold AUTL as of Q4 2024.

  • David Shaw reported no remaining Autolus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • David Shaw sold 91,687 Autolus Therapeutics shares in Q4 2024, an estimated $333K.
  • David Shaw first reported a position in Autolus Therapeutics in Q2 2021 and held it in 5 quarters.
  • David Shaw's Autolus Therapeutics position peaked at $4.13M in Q1 2024.
  • 110 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.